Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7701)	2/13/2000 7:38:00 AM
From: Mel Spivak	Read Replies (2) \| Respond to of 8116

CYTO - What it is all about: I lifted this from a post on clearstation.com : CYTOGEN is heavily involved in two areas. One area is diagnostics and therapeutics of ovarian, colorectal and prostate cancer. They have FDA approved products for imaging and diagnostics of these cancers. They have an FDA approved product called Quadremet for the treatment of metastatic bone cancer. The second prong of their company is genomics and proteomics. Their proteomics library is second to none. And, is growing faster than all other companies. Medicine is moving into a new therapeutic arena. The new medicine involves molecular and submolecular entities derived from the genetic code and its protein derivatives. Both are indispensible to the other, however proteins are at the very center of all life chemical reactions and activities. This company is about where HGSI was a year ago. The great thing is that CYTO now has FDA approved products on the market where as HGSI does not. In my opinion Cytogen has the potential to overtake and pass HGSI from both a medical and a business standpoint. Dr. R I am long on CYTO. Mel